Tango Therapeutics Inc

Tango Therapeutics reported a second-quarter 2026 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 31 cents, as higher operating expenses weighed on results. The company had reported a loss of 35 cents per share in the year-ago quarter, and collaboration revenues fell to zero from $3.2 million a year earlier after all remaining deferred revenues under the truncated Gilead collaboration were recognized during 2025. Research and development expenses rose 13% year over year to $37.2 million, driven mainly by higher spending on the vopimetostat and TNG456 clinical programs, while general and administrative expenses nearly doubled to $22.6 million on higher personnel-related costs including share-based compensation. Over the past month the consensus estimate has shifted -10.16%, and the stock carries a Zacks Rank #3 (Hold) with an aggregate VGM Score of F. Shares of Tango Therapeutics have lost about 6.2% since the last earnings report, underperforming the S&P 500.